289 related articles for article (PubMed ID: 36496302)
21. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H
Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
24. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
25. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
26. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
28. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract][Full Text] [Related]
29. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.
Fu S; Zhang Q; Jing R; Zu C; Ni F; Lv Y; Cui J; Zheng H; Zhang Y; Zhang M; Wei G; Cen Z; Chang AH; Hu Y; Huang H
Bone Marrow Transplant; 2023 Jun; 58(6):701-709. PubMed ID: 37002410
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract][Full Text] [Related]
31. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.
Das S; Ailawadhi S; Sher T; Roy V; Fernandez A; Parrondo RD
Curr Oncol; 2023 Oct; 30(11):9627-9633. PubMed ID: 37999117
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
33. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
34. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
35. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
37. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
39. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
[TBL] [Abstract][Full Text] [Related]
40. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].
Xu XZ; Liu R; Zhao WH; Yang Y; Liu J; Zhang WG; Bai J; He AL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):838-844. PubMed ID: 38049336
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
